CL2014000297A1 - Uso de un inhibidores de corrientes "funny" (if) o una de sus sales para utilizar en un metodo de tratamiento y prevencion de la insuficiencia cardiaca en felinos . - Google Patents
Uso de un inhibidores de corrientes "funny" (if) o una de sus sales para utilizar en un metodo de tratamiento y prevencion de la insuficiencia cardiaca en felinos .Info
- Publication number
- CL2014000297A1 CL2014000297A1 CL2014000297A CL2014000297A CL2014000297A1 CL 2014000297 A1 CL2014000297 A1 CL 2014000297A1 CL 2014000297 A CL2014000297 A CL 2014000297A CL 2014000297 A CL2014000297 A CL 2014000297A CL 2014000297 A1 CL2014000297 A1 CL 2014000297A1
- Authority
- CL
- Chile
- Prior art keywords
- funny
- felines
- prevention
- salts
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Birds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11177354 | 2011-08-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2014000297A1 true CL2014000297A1 (es) | 2014-09-22 |
Family
ID=46639540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2014000297A CL2014000297A1 (es) | 2011-08-12 | 2014-02-06 | Uso de un inhibidores de corrientes "funny" (if) o una de sus sales para utilizar en un metodo de tratamiento y prevencion de la insuficiencia cardiaca en felinos . |
Country Status (14)
Country | Link |
---|---|
US (3) | US20130040937A1 (es) |
EP (3) | EP3318247A1 (es) |
JP (2) | JP2014521714A (es) |
KR (2) | KR20140053307A (es) |
CN (2) | CN103796638A (es) |
AR (2) | AR089645A1 (es) |
AU (2) | AU2012296925A1 (es) |
BR (2) | BR112014003117A2 (es) |
CA (2) | CA2841549A1 (es) |
CL (1) | CL2014000297A1 (es) |
CO (2) | CO6880067A2 (es) |
MX (2) | MX2014001557A (es) |
RU (2) | RU2014109079A (es) |
WO (2) | WO2013024023A1 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050070537A1 (en) | 2002-10-10 | 2005-03-31 | Chris Rundfeldt | Use of dihydroimidazolones for the treatment of dogs |
EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
RU2014109079A (ru) | 2011-08-12 | 2015-09-20 | Бёрингер Ингельхайм Ветмедика Гмбх | Фармацевтическая композиция с маскированным вкусом |
EP2825159B1 (en) | 2012-03-15 | 2022-06-22 | Boehringer Ingelheim Vetmedica GmbH | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
EP2953612A1 (en) * | 2013-02-11 | 2015-12-16 | Boehringer Ingelheim Vetmedica GmbH | Kit-of-parts |
AU2014292086B2 (en) | 2013-07-19 | 2019-08-08 | Boehringer Ingelheim Vetmedica Gmbh | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
US20150164047A1 (en) * | 2013-11-07 | 2015-06-18 | Urban Pet Haus, LLC | Edible cat toy |
GB201319791D0 (en) * | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
EP2925305B1 (en) | 2013-12-04 | 2016-07-27 | Boehringer Ingelheim Vetmedica GmbH | Improved pharmaceutical compositions of pimobendan |
EP3110403B1 (en) | 2014-02-25 | 2019-11-06 | Orbis Biosciences, Inc. | Taste masking drug formulations |
US9820988B2 (en) * | 2014-03-24 | 2017-11-21 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of epileptic disorders in feline animals |
TW201629140A (zh) * | 2015-02-09 | 2016-08-16 | Genepharm Biotech Corp | 可成膜的凝膠組成物 |
JP5941592B1 (ja) * | 2015-12-24 | 2016-06-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | フィルムコーティングを施した着色固形製剤 |
EP3429559B1 (en) * | 2016-03-15 | 2022-04-13 | Acer Therapeutics Inc. | Palatable compositions including sodium phenylbutyrate and uses thereof |
US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
KR102533941B1 (ko) * | 2016-04-25 | 2023-05-17 | 캔 테크놀로지스 인코포레이티드 | 용해성 미세 성분 컨테이너 및 상기 컨테이너를 사용한 동물 사료 제조 방법 |
CA3022399A1 (en) | 2016-04-26 | 2017-11-02 | Orbis Biosciences, Inc. | Biodegradable polymer microsphere compositions for parenteral administration |
CN110769816B (zh) * | 2017-05-19 | 2022-12-06 | 比斯坎神经治疗公司 | 石杉碱的改良释放药物组合物以及其使用方法 |
CN108969496A (zh) * | 2018-09-07 | 2018-12-11 | 江苏恒丰强生物技术有限公司 | 一种宠物用盐酸贝那普利咀嚼片及其制备方法 |
CN114599353A (zh) * | 2019-10-23 | 2022-06-07 | 皮埃蒙特动物健康公司 | 匹莫苯制剂及其使用方法 |
JP7482645B2 (ja) * | 2020-02-18 | 2024-05-14 | 沢井製薬株式会社 | 核粒子を含む顆粒の製造方法 |
CN216570857U (zh) * | 2021-08-11 | 2022-05-24 | Acer治疗公司 | 改善药物物质适口性的剂型和多个剂型 |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE759125A (fr) | 1969-11-19 | 1971-05-18 | Boehringer Sohn Ingelheim | Nouvelles n-allyl-2-arylamino-imidazolines-(2) substituees et procedes pour les fabriquer |
DE2756113A1 (de) | 1977-12-16 | 1979-06-21 | Thomae Gmbh Dr K | Neue 4-hydroxy-2h-1,2-benzothiazin- 3-carboxamid-1,1-dioxide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
ES8101067A1 (es) | 1978-08-25 | 1980-12-01 | Thomae Gmbh Dr K | Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona |
DE3119874A1 (de) | 1981-05-19 | 1982-12-09 | Dr. Karl Thomae Gmbh, 7950 Biberach | "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel" |
DE3333639A1 (de) | 1983-09-17 | 1985-03-28 | Dynamit Nobel Ag | Zubereitung von nitroestern fuer die koronartherapie |
US5175157A (en) | 1985-11-27 | 1992-12-29 | Boehringer Ingelheim Gmbh | Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them |
DE3717561A1 (de) | 1987-05-25 | 1988-12-08 | Thomae Gmbh Dr K | Indol-, isochinolin- und benzazepinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
DE3541811A1 (de) | 1985-11-27 | 1987-06-04 | Thomae Gmbh Dr K | Neue cyclische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
US4874613A (en) | 1987-03-06 | 1989-10-17 | Baker Cummins Pharmaceuticals, Inc. | Taste concealing pharmaceutical dosage unit |
DE3736866A1 (de) | 1987-10-30 | 1989-05-11 | Thomae Gmbh Dr K | Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz |
DE3805635A1 (de) | 1988-02-24 | 1989-09-07 | Thomae Gmbh Dr K | Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica |
US4980175A (en) * | 1989-01-03 | 1990-12-25 | Leonard Chavkin | Liquid orally administrable compositions based on edible oils |
US5082669A (en) | 1989-07-20 | 1992-01-21 | Dainippon Pharmaceutical Co., Ltd. | Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked |
FR2681862B1 (fr) | 1991-09-27 | 1993-11-12 | Adir Cie | Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent. |
US5954049A (en) | 1991-10-15 | 1999-09-21 | Trudell Medical Limited | Equine mask with MDI adapter |
US5308853A (en) | 1991-12-20 | 1994-05-03 | Warner-Lambert Company | Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties |
DE4200821A1 (de) | 1992-01-15 | 1993-07-22 | Bayer Ag | Geschmacksmaskierte pharmazeutische mittel |
RU2078536C1 (ru) | 1993-09-02 | 1997-05-10 | Украинский научно-исследовательский институт кардиологии им.акад.Н.Д.Стражеско | Способ определения клинической эффективности применения верапамила и дилтиазема у больных гипертрофической кардиомиопатией |
BR9407613A (pt) | 1993-09-24 | 1997-01-14 | Procter & Gamble | Novos compostos deoxi e 14-amino esteróide contendo açúcar substituído com oxigênio |
US5595987A (en) | 1994-07-22 | 1997-01-21 | The Trustees Of Columbia University In The City Of New York | Method of slowing ventricular arrhythmias using zatebradine |
US5760069A (en) | 1995-02-08 | 1998-06-02 | Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 | Method of treatment for decreasing mortality resulting from congestive heart failure |
DE19532668A1 (de) | 1995-09-05 | 1997-03-06 | Dresden Arzneimittel | Neue, antikonvulsiv wirkende 1-Ar(alk)yl-imidazolin-2-one, die in 4-Stellung einen disubstituierten Amin-Rest enthalten, und Verfahren zu deren Herstellung |
US5828394A (en) | 1995-09-20 | 1998-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Fluid drop ejector and method |
DE19706978A1 (de) | 1997-02-21 | 1998-08-27 | Ulrich Dr Posanski | Kombinationspräparat für oral applizierbare Antibiotika |
US5840329A (en) * | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
US6083991A (en) | 1997-06-04 | 2000-07-04 | University Of Florida Research Foundation, Inc. | Anti-arrhythmic composition and methods of treatment |
DE19741635A1 (de) | 1997-09-22 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
JP4240173B2 (ja) | 1998-06-03 | 2009-03-18 | 日産化学工業株式会社 | インダン誘導体 |
EP1870098A3 (en) | 1998-07-10 | 2010-07-07 | Novartis Ag | Combined use of valsartan and calcium channel blockers for therapeutic purposes |
US6204281B1 (en) | 1998-07-10 | 2001-03-20 | Novartis Ag | Method of treatment and pharmaceutical composition |
WO2000075133A1 (fr) | 1999-06-03 | 2000-12-14 | Yamanouchi Pharmaceutical Co., Ltd. | Derives d'isoquinoline ou leurs sels |
US6395728B2 (en) | 1999-07-08 | 2002-05-28 | Novartis Ag | Method of treatment and pharmaceutical composition |
US8226598B2 (en) | 1999-09-24 | 2012-07-24 | Tolmar Therapeutics, Inc. | Coupling syringe system and methods for obtaining a mixed composition |
DE10018401A1 (de) | 2000-04-13 | 2001-10-25 | Boehringer Ingelheim Pharma | Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen |
DE10062712A1 (de) | 2000-12-15 | 2002-06-20 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden |
EA007485B1 (ru) | 2001-02-24 | 2006-10-27 | Берингер Ингельхайм Фарма Гмбх Унд Ко. Кг | Производные ксантина, способ их получения, фармацевтическая композиция на их основе и способ ее получения |
CO5400144A1 (es) | 2002-03-11 | 2004-05-31 | Novartis Ag | Compuestos organicos |
US20040138306A1 (en) | 2002-07-25 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
DE60200160T2 (de) | 2002-07-25 | 2004-11-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Cilobradine oder pharmazeutisch akzeptablen Salze zur Behandlung oder Prävention von Herzversagen |
CA2435526A1 (en) | 2002-07-25 | 2004-01-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of cyclic amine derivatives or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
CA2496411A1 (en) | 2002-08-20 | 2004-03-04 | Protemix Corporation Limited | Dosage forms and related therapies |
US20050070537A1 (en) | 2002-10-10 | 2005-03-31 | Chris Rundfeldt | Use of dihydroimidazolones for the treatment of dogs |
JP4266117B2 (ja) | 2003-03-03 | 2009-05-20 | リコーエレメックス株式会社 | 超音波流量計 |
AU2004241746A1 (en) | 2003-05-22 | 2004-12-02 | Nycomed Gmbh | Salmeterol and ciclesonide combination |
US20060147531A1 (en) * | 2003-07-01 | 2006-07-06 | Mojca Segula | Tamsulosin core with a coating of polyvinylpyrrolidone and polyfinylacetate |
UA87982C2 (ru) | 2003-07-11 | 2009-09-10 | Берингер Ингельхайм Ветмедика Гмбх | Способ лечения или предотвращения расстройств центральной нервной системы производными 1-ар(алк)-4-пиперидиноимидазолин-2-она, фармацевтическая композиция |
PE20050941A1 (es) | 2003-12-16 | 2005-11-08 | Nycomed Gmbh | Suspensiones acuosas de ciclesonida para nebulizacion |
AU2005219508B2 (en) | 2004-02-18 | 2012-02-16 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthine, the production thereof and the use in the form of a DPP inhibitor |
DE102004011512B4 (de) | 2004-03-08 | 2022-01-13 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische Zubereitung enthaltend Pimobendan |
WO2005105045A1 (ja) | 2004-04-30 | 2005-11-10 | Astellas Pharma Inc. | 経口投与用時限放出型粒子状医薬組成物及び該組成物を含有する口腔内速崩壊錠 |
TWI415635B (zh) | 2004-05-28 | 2013-11-21 | 必治妥施貴寶公司 | 加衣錠片調製物及製備彼之方法 |
JP2008504341A (ja) | 2004-06-29 | 2008-02-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ステロイドと抗コリン作用剤とを含む吸入用薬剤 |
WO2006046256A1 (en) * | 2004-10-27 | 2006-05-04 | Alembic Limited | Extended release formulation of pramipexole dihydrochloride |
DK1830814T3 (da) | 2005-01-06 | 2009-08-03 | Cima Labs Inc | Smagsmaskeret formulering til ikke-plastificerende lægemidler |
JP2006327943A (ja) * | 2005-05-23 | 2006-12-07 | Towa Yakuhin Kk | 経時的溶出遅延を抑制したテイストマスク錠剤 |
JP2007015966A (ja) * | 2005-07-06 | 2007-01-25 | Fujimoto Corporation:Kk | 口腔内崩壊錠 |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
EP1762179A1 (en) * | 2005-09-07 | 2007-03-14 | Boehringer Ingelheim Vetmedica Gmbh | Method for improving diagnostic quality in echocardiography |
US20070098746A1 (en) * | 2005-11-02 | 2007-05-03 | Nichols William M | Multi-layered coating technology for taste masking |
US20080015539A1 (en) | 2006-02-28 | 2008-01-17 | Robert Pieroni | Bottle with adapter for receiving needleless syringe |
PL1880718T3 (pl) * | 2006-07-10 | 2012-02-29 | Dr R Pfleger Chemische Fabrik Gmbh | Preparat farmaceutyczny do podawania doustnego o kontrolowanym uwalnianiu w jelicie cienkim i sposób jego wytwarzania |
UY30542A1 (es) | 2006-08-18 | 2008-03-31 | Boehringer Ingelheim Int | Formulacion de aerosol para la inhalacion de agonistas beta |
UY30543A1 (es) | 2006-08-18 | 2008-03-31 | Boehringer Ingelheim Int | Formulacion de aerosol para la inhalacion de beta- agonistas |
BRPI0716196A2 (pt) | 2006-08-31 | 2013-11-12 | Eurand Inc | Sistemas de distribuição de fármacos que compreendem soluções sólidas de fármacos fracamente básicos. |
JP2008081448A (ja) * | 2006-09-28 | 2008-04-10 | Kowa Pharmaceutical Co Ltd | 酒石酸ゾルピデムの苦味マスキング速放性粒子 |
US20100055181A1 (en) | 2006-12-18 | 2010-03-04 | Lupin Limited | Controlled release dosage forms of zolpidem |
US20090022786A1 (en) | 2007-07-16 | 2009-01-22 | Yung Shin Pharm. Ind. Co., Ltd. | Oral pharmaceutical dosage form and manufacturing method thereof |
EP2127643A1 (de) | 2008-05-30 | 2009-12-02 | Bayer Schering Pharma Aktiengesellschaft | Orale Pelletformulierungen mit zeitversetzter Wirkstofffreigabe |
IT1393244B1 (it) | 2008-07-18 | 2012-04-12 | Universita' Degli Studi Di Milano | Sistema per il rilascio al colon di farmaci suscettibili di degradazione enzimatica e/o scarsamente assorbiti nel tratto gastrointestinale |
US20120207825A1 (en) * | 2009-09-17 | 2012-08-16 | Sunilendu Bhushan Roy | Pharmaceutical compositions for reducing alcohol-induced dose dumping |
US7829748B1 (en) | 2009-09-21 | 2010-11-09 | Honeywell International Inc. | Process for the manufacture of 1,3,3,3-tetrafluoropropene |
HUE035588T2 (en) | 2010-02-12 | 2018-05-28 | Krka D D Novo Mesto | Form of ivabradine hydrochloride |
EP2368552A1 (en) | 2010-03-25 | 2011-09-28 | Boehringer Ingelheim Vetmedica GmbH | 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal |
RU2014109079A (ru) | 2011-08-12 | 2015-09-20 | Бёрингер Ингельхайм Ветмедика Гмбх | Фармацевтическая композиция с маскированным вкусом |
EP2931262A1 (en) | 2012-12-14 | 2015-10-21 | Boehringer Ingelheim Vetmedica GmbH | Funny current (if) inhibitors for use in a method of treating and preventing heart disease in canine |
LT2934479T (lt) | 2012-12-21 | 2018-12-27 | Boehringer Ingelheim Vetmedica Gmbh | Ciklezonidas, skirtas arklių kvėpavimo takų ligų gydymui |
EP2953612A1 (en) | 2013-02-11 | 2015-12-16 | Boehringer Ingelheim Vetmedica GmbH | Kit-of-parts |
-
2012
- 2012-08-10 RU RU2014109079/15A patent/RU2014109079A/ru not_active Application Discontinuation
- 2012-08-10 AR ARP120102946A patent/AR089645A1/es active Pending
- 2012-08-10 BR BR112014003117A patent/BR112014003117A2/pt not_active Application Discontinuation
- 2012-08-10 AU AU2012296925A patent/AU2012296925A1/en not_active Abandoned
- 2012-08-10 MX MX2014001557A patent/MX2014001557A/es unknown
- 2012-08-10 AU AU2012296938A patent/AU2012296938A1/en not_active Abandoned
- 2012-08-10 WO PCT/EP2012/065680 patent/WO2013024023A1/en active Application Filing
- 2012-08-10 WO PCT/EP2012/065704 patent/WO2013024036A1/en active Application Filing
- 2012-08-10 CA CA2841549A patent/CA2841549A1/en not_active Abandoned
- 2012-08-10 EP EP17201489.6A patent/EP3318247A1/en not_active Ceased
- 2012-08-10 JP JP2014524403A patent/JP2014521714A/ja active Pending
- 2012-08-10 AR ARP120102947A patent/AR089646A1/es active Pending
- 2012-08-10 EP EP12751035.2A patent/EP2741736B1/en active Active
- 2012-08-10 KR KR1020147006548A patent/KR20140053307A/ko not_active Application Discontinuation
- 2012-08-10 CN CN201280044244.9A patent/CN103796638A/zh active Pending
- 2012-08-10 JP JP2014524397A patent/JP2014521713A/ja active Pending
- 2012-08-10 CN CN201280044245.3A patent/CN103781468A/zh active Pending
- 2012-08-10 KR KR1020147006549A patent/KR20140057604A/ko not_active Application Discontinuation
- 2012-08-10 CA CA2843100A patent/CA2843100A1/en not_active Abandoned
- 2012-08-10 MX MX2014001556A patent/MX2014001556A/es unknown
- 2012-08-10 BR BR112014003061A patent/BR112014003061A2/pt not_active IP Right Cessation
- 2012-08-10 EP EP12744014.7A patent/EP2741735A1/en not_active Withdrawn
- 2012-08-10 RU RU2014109074/15A patent/RU2014109074A/ru not_active Application Discontinuation
- 2012-08-13 US US13/584,657 patent/US20130040937A1/en not_active Abandoned
- 2012-08-13 US US13/584,806 patent/US8741350B2/en active Active
-
2014
- 2014-02-06 CL CL2014000297A patent/CL2014000297A1/es unknown
- 2014-02-13 CO CO14031182A patent/CO6880067A2/es not_active Application Discontinuation
- 2014-02-13 CO CO14031179A patent/CO6880066A2/es not_active Application Discontinuation
- 2014-04-16 US US14/254,136 patent/US9289390B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AR089646A1 (es) | 2014-09-10 |
CN103781468A (zh) | 2014-05-07 |
AU2012296925A1 (en) | 2014-02-06 |
KR20140057604A (ko) | 2014-05-13 |
CO6880066A2 (es) | 2014-02-28 |
MX2014001556A (es) | 2014-03-31 |
BR112014003061A2 (pt) | 2017-02-21 |
CA2841549A1 (en) | 2013-02-21 |
JP2014521714A (ja) | 2014-08-28 |
US8741350B2 (en) | 2014-06-03 |
JP2014521713A (ja) | 2014-08-28 |
RU2014109074A (ru) | 2015-09-20 |
AR089645A1 (es) | 2014-09-10 |
MX2014001557A (es) | 2014-03-31 |
WO2013024023A1 (en) | 2013-02-21 |
KR20140053307A (ko) | 2014-05-07 |
US20130040937A1 (en) | 2013-02-14 |
WO2013024036A1 (en) | 2013-02-21 |
EP2741735A1 (en) | 2014-06-18 |
EP2741736B1 (en) | 2017-11-22 |
US20140227351A1 (en) | 2014-08-14 |
CO6880067A2 (es) | 2014-02-28 |
AU2012296938A1 (en) | 2014-02-13 |
US9289390B2 (en) | 2016-03-22 |
CA2843100A1 (en) | 2013-02-21 |
RU2014109079A (ru) | 2015-09-20 |
BR112014003117A2 (pt) | 2017-06-13 |
US20130084332A1 (en) | 2013-04-04 |
EP2741736A1 (en) | 2014-06-18 |
EP3318247A1 (en) | 2018-05-09 |
CN103796638A (zh) | 2014-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2014000297A1 (es) | Uso de un inhibidores de corrientes "funny" (if) o una de sus sales para utilizar en un metodo de tratamiento y prevencion de la insuficiencia cardiaca en felinos . | |
CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
EA201500934A1 (ru) | Кардио- и нефропротективная противодиабетическая терапия | |
CL2013001602A1 (es) | Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple. | |
CL2014003121A1 (es) | Formulacion liquida que comprende propilenglicol y un inodilatador, un inhibidor de la enzima convertidora de angiotensina o una combinacion de ambos; proceso para prepararla; kit; y metodo de tratamiento de una enfermedad cardiaca y/o hipertension. | |
BR112015002541A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente. | |
BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
BR112012000882A2 (pt) | Preparação cosmética capilar e método para aplicação. | |
CL2014002880A1 (es) | Compuestos derivados de heterociclos nitrogenados o sus sales, inhibidores selectivos de la pde2a; medicamento que los comprende; y su uso para la profilaxis y tratamiento de la esquizofrenia. | |
CL2015000345A1 (es) | Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib. | |
UY34280A (es) | Nuevos compuestos que tienen actividad inhibidora frente a la daminoacido oxidasa. | |
HK1215540A1 (zh) | 用於治療或預防疾病的因子 蛋白、因子 蛋白及其抑制劑 | |
BR112015005369A2 (pt) | inibidores de usp30 e métodos para sua utilização | |
WO2012158672A3 (en) | Compounds for use in treatment of mucositis | |
CL2014000267A1 (es) | Formulacion farmaceutica liquida que comprende ketoprofeno, amitriptilina y oximetazolina; kit farmaceutico; metodo para prevenir o tratar la inflamacion. | |
BR112015027477A2 (pt) | método para tratamento de um transtorno de deglutição | |
BR112014031512A2 (pt) | composição cosmética e método para o tratamento cosmético. | |
AR094241A1 (es) | Ciclesonida para el tratamiento de la enfermedad de las vias respiratorias en caballos | |
BR112013012175A2 (pt) | combinação, coadministração, uso e método | |
IT1400837B1 (it) | Metodo per la preparazione e uso di biocidi arricchiti in radicali attivi prima dell'uso. | |
AR080933A1 (es) | Tratamiento de esclerosis multiple con masitinib | |
CY1117890T1 (el) | Χρηση αλατων του 3-καρβοξυ-ν-αιθυλο-ν,ν-διμεθυλοπροπαν-1-αμινιου στη θεραπεια καρδιαγγειακης νοσου | |
ES2721003T3 (es) | Utilización de ácido 1, 3 - propano disulfónico o sales farmacéuticamente aceptables del mismo para el tratamiento de la sarcoidosis | |
BR112013017444A2 (pt) | método de determinar o risco para o desenvolvimento da doença de alzheimer em um indivíduo, de tratar um indivíduo para a doença de alzheimer e de determinar um risco para desenvolver a doença de alzheimer em um paciente |